2020 Highlights
Montefiore Einstein Cancer Center
In 2020, the Montefiore Einstein Cancer Center not only provided outstanding clinical care to our patients, it also offered the social and emotional support needed during the COVID-19 pandemic. Despite the challenges presented by an unprecedented year, we made remarkable achievements in clinical, programmatic and research settings.
DATA & STATISTICS
2020 by the numbers
See why 2020 was a remarkable year for us
Explore the numbers 
$80M
Dollars in research funding from the NCI, NIH and other sources
169
Active protocols
251
Therapeutic clinical trial accruals
19
Inpatient, outpatient and community-based locations
Innovations and Achievements
Pioneering the future of treatment and care
Taking a stand against racial inequality and injustice
In a year marked by social and political upheaval, Montefiore Einstein Cancer Center stood with healthcare colleagues across the country and around the world in the White Coats for Black Lives movement.
Research Review
Improving care and outcomes through research
Over the course of 2020, we published on a wide variety of topics, including CAR T-cell therapy, chemotherapy benefits in breast cancer and the impact of COVID-19 on cancer patients.
Clinical Trials
Advancing care through clinical trials
In 2020, Montefiore Einstein Cancer Center had 251 therapeutic clinical trial accruals, 169 of which were active protocols, including interventions addressing a broad range of solid tumors and hematologic malignancies. Below is a list of featured active protocols from last year.
FLT3 Ligand, CD40 Agonist Antibody, and Stereotactic Radiotherapy Versus Standard Therapy for Advanced Non-small Cell Lung Cancer: A Phase I/II Randomized Trial
Nitin Ohri, MD
An Open Label Dose Escalation Trial of CA-4948 in Patients with Acute Myelogenous Leukemia or Myelodysplastic Syndrome: IRAK4 Inhibitor in MDS/AML
Amit Verma, MD
A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma (CARTITUDE-2)
Phase II Study to Evaluate the Efficacy and Safety of Sirolimus in Subjects with Metastatic, Mismatch Repair Deficient Solid Tumors After Immunotherapy
Sanjay Goel, MD
Testing the Combination of the Anti-Cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients with Advanced Cancer and HIV
Haiying Cheng, MD, PhD
Team News
Updates and additions to our world-renowned faculty
Patient referrals
At Montefiore Einstein Cancer Center, we know providing patients with the best possible care includes teamwork and trust. We work closely with our valued referring physicians to ensure open communication and reliable expertise.
Contact us
Anne McDarby
Associate Director, Network Program Management
Montefiore Einstein Cancer Center
1-718-862-8840 /ext. 460
amcdarby@montefiore.org
Montefiore Einstein Cancer Center
Montefiore.org
Einsteinmed.org